NEW YORK (GenomeWeb News) – Rosetta Genomics, a developer of microRNA-based diagnostics and therapeutics based in Rehovot, Israel, has filed papers with the US Securities and Exchange Commission for an initial public offering.
 
According to the SEC filing, dated Sept. 1, the privately held firm plans to sell 3 million shares at $11 to $13 per share, for a maximum offering price of $44.85 million.
 
The company said it has applied to list its shares on the Nasdaq Global Market under the symbol “ROSG.”

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.